Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA901 extension study in advanced renal cell carcinoma
2008-000213-30Phase 2Completed
- Sponsor
- Immatics
- Start
- Feb 2008
- Modality
- Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMA901 and sargramostim in renal cell carcinoma (RCC), sponsored by Immatics. Primary endpoint: Long-term safety. Started Feb 2008; status: completed.
02
Drugs
IMA901sargramostim
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2008-000213-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000213-30.